Trial · NCT03172026
Maraviroc to Augment Rehabilitation Outcomes After Stroke
NCT03172026, Phase 2, Phase 3, Terminated, University of California, Los Angeles; results first posted 2021-08-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Maraviroc to Augment Rehabilitation Outcomes After Stroke. Trials, record NCT03172026. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03172026
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Maraviroc to Augment Rehabilitation Outcomes After Stroke
- NCT number
- NCT03172026
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 2 participants, actual
- Lead sponsor
- University of California, Los Angeles
- Conditions
- Stroke
- Interventions
- Maraviroc 300 mg, Rehabilitation therapy, Placebo 300 mg
- First posted
- 2017-05-31
- Last updated
- 2021-08-03
- Results first posted
- 2021-08-03
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in 10 Meter Walk Test | Baseline, 6 months post | Timed walking speed over 10 meters. The evaluable sample size of 30 in each group will have 80% power to detect a difference in means of -0.206 (m/s), the difference between an assumed usual care walking speed of 0.51 (SD=0.28) and an assumed intervention group mean walking speed of 0.716. This assumes a common standard deviation in the two groups and a two group t-test with a 0.05 two-sided significance level. The estimates for the mean and standard deviation for walking speed come from the LEAPS RCT (Duncan, N Engl J Med, 2011). The t-test used for the power calculation is a simplification of the mixed effects analysis plan for the primary endpoints. |
| Primary | Change in Action Research Arm Test | Baseline, 6 months post | Assessment of upper extremity function. Our sample size of 30 for each group is based on a statistical power of 80% with an alpha of 5% for detecting a meaningful difference of 6 points, i.e., a 10% change, which has been suggested by several completed trials. In a stroke trial, the standard deviation was 8 points measured at 2 weeks post stroke. |
| Secondary | Change in Fugl-Meyer Motor Score | Baseline, within 5 days of last medication dose (8 weeks), at 6 months post stroke | Assessment of arm and leg impairment after stroke |
| Secondary | Change in Stroke Impact Scale | Baseline, within 5 days of last medication dose (8 weeks), at 6 months post stroke | Self-report questionnaire on quality of life post-stroke |
| Secondary | Change in 6 Minute Walking Distance | Baseline, within 5 days of last medication dose (8 weeks), at 6 months post stroke | Distance walked in a 6 minute time period |
| Secondary | Change in Physical Activity Enjoyment Scale | Baseline, within 5 days of last medication dose (8 weeks), at 6 months post stroke | Self-report questionnaire related to exercise enjoyment |
| Secondary | Change in Activity Self Efficacy | Baseline, within 5 days of last medication dose (8 weeks), at 6 months post stroke | Self-report questionnaire related to confidence in increasing activity and maintaining exercise routines |
| Secondary | Change in International Physical Activity Questionnaire | Baseline, within 5 days of last medication dose (8 weeks), at 6 months post stroke | Self-report of activity levels |
| Secondary | Change From Baseline in Walking Activity, Sensors | Collected daily for 8 weeks | Sedentary time |
| Secondary | Upper Extremity Practice, Sensors | Collected daily for 8 weeks | Amount of time practicing |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in 10 Meter Walk Test | Baseline, 6 months post | Participants exited study prior to 6 month assessment | ||
| PRIMARY | Change in Action Research Arm Test | Baseline, 6 months post | Participants exited study prior to 6 month assessment | ||
| SECONDARY | Change in Fugl-Meyer Motor Score | Baseline, within 5 days of last medication dose (8 weeks), at 6 months post stroke | Participants exited study prior to 8 week assessment | ||
| SECONDARY | Change in Stroke Impact Scale | Baseline, within 5 days of last medication dose (8 weeks), at 6 months post stroke | Participants exited study prior to 8 week assessment | ||
| SECONDARY | Change in 6 Minute Walking Distance | Baseline, within 5 days of last medication dose (8 weeks), at 6 months post stroke | Participants exited study prior to 8 week assessment | ||
| SECONDARY | Change in Physical Activity Enjoyment Scale | Baseline, within 5 days of last medication dose (8 weeks), at 6 months post stroke | Participants exited study prior to 8 week assessment | ||
| SECONDARY | Change in Activity Self Efficacy | Baseline, within 5 days of last medication dose (8 weeks), at 6 months post stroke | Participants exited study prior to 8 week assessment | ||
| SECONDARY | Change in International Physical Activity Questionnaire | Baseline, within 5 days of last medication dose (8 weeks), at 6 months post stroke | Participants exited study prior to 8 week assessment | ||
| SECONDARY | Change From Baseline in Walking Activity, Sensors | Collected daily for 8 weeks | Participants exited study prior to assessment | ||
| SECONDARY | Upper Extremity Practice, Sensors | Collected daily for 8 weeks | Participants exited study prior to complete assessment |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 outcomesResults by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow10
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Maraviroc + Augmented Rehabilitation | 2 | |
| Overall Study | STARTED | Placebo + Augmented Rehabilitation | 0 | |
| Overall Study | 8 Week Assessment | Maraviroc + Augmented Rehabilitation | 0 | |
| Overall Study | 8 Week Assessment | Placebo + Augmented Rehabilitation | 0 | |
| Overall Study | 6 Month Assessment | Maraviroc + Augmented Rehabilitation | 0 | |
| Overall Study | 6 Month Assessment | Placebo + Augmented Rehabilitation | 0 | |
| Overall Study | COMPLETED | Maraviroc + Augmented Rehabilitation | 0 | |
| Overall Study | COMPLETED | Placebo + Augmented Rehabilitation | 0 | |
| Overall Study | NOT COMPLETED | Maraviroc + Augmented Rehabilitation | 2 | |
| Overall Study | NOT COMPLETED | Placebo + Augmented Rehabilitation | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Maraviroc + Augmented Rehabilitation | 0 | 2 |
| Total, all-cause mortality | Placebo + Augmented Rehabilitation | 0 | 0 |
| Total, other adverse events | Maraviroc + Augmented Rehabilitation | 0 | 2 |
| Total, other adverse events | Placebo + Augmented Rehabilitation | 0 | 0 |
| Total, serious adverse events | Maraviroc + Augmented Rehabilitation | 0 | 2 |
| Total, serious adverse events | Placebo + Augmented Rehabilitation | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03172026
GET https://conductscience.org/api/trials/v1/NCT03172026/registered